Magazine Article | August 1, 2022

KemPharm: Converting FDA Complete Response Letters Into New Opportunities

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

It’s not easy to carve out a niche in today’s biopharmaceutical industry. No matter how innovative or unique a pipeline is, or how brilliant and motivating a leader may be, there is always a competitor (or three) waiting in the wings. Fresh off its $12.8 million fire sale acquisition of Danish biopharma Orphazyme, KemPharm, a Celebration, FL-based specialty pharmaceutical company, is betting that its past experiences in rehabbing drugs for regulatory approval — following FDA complete response letters — is a novel capability that can boost the company into a lucrative drug market for rare neurological and CNS disorders.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: